Vir Biotechnology, Inc. (Nasdaq: VIR) announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 12, 2026, according to a company statement.

Liu will oversee clinical development, medical affairs, and regulatory affairs at the San Francisco-based clinical-stage biopharmaceutical company.

Liu joins Vir Biotechnology from Nuvation Bio, where he served as Chief Medical Officer. Before that, he held the same role at 3D Medicines. Earlier in his career, he served as Executive Medical Director at Celgene Corporation and held leadership positions at Bristol Myers Squibb and AstraZeneca.

Liu holds an M.D. from Beijing Medical University, an M.S. in Pharmaceutical Sciences from the University of Toledo, and a Ph.D. in Bioengineering from the Massachusetts Institute of Technology.

Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology, said Liu brings "extensive immuno-oncology leadership experience" and a "strong track record of advancing and securing approvals for innovative cancer therapies."

Vir Biotechnology's current pipeline includes a Phase 3 program for chronic hepatitis delta and a portfolio of T-cell engager therapies targeting solid tumor indications.